hVIVO PLC Change of registered address
02 Juillet 2024 - 8:02AM
RNS Regulatory News
RNS Number : 6802U
hVIVO PLC
02 July 2024
hVIVO plc
("hVIVO", the "Company" or the
"Group")
Change of registered
address
hVIVO plc (AIM & Euronext:
HVO), a fast growing specialist contract
research organisation (CRO) and world leader in testing infectious
and respiratory disease products using human challenge clinical
trials, announces that the Company's registered
address has changed to Floor 24, 40 Bank Street, London, E14
5NR, United Kingdom.
For further information please
contact:
hVIVO plc
|
+44 (0) 20
7756 1300
|
Yamin 'Mo' Khan, Chief Executive Officer
Stephen Pinkerton, Chief Financial
Officer
|
|
|
|
Cavendish Capital Markets Limited (Nominated Adviser and Joint
Broker)
|
+44 (0) 20
7220 0500
|
Geoff Nash, Charlie Beeson, Nigel
Birks, Harriet Ward
|
|
|
|
Peel Hunt LLP (Joint Broker)
|
+44 (0)20
7418 8900
|
James Steel, Dr Christopher Golden
|
|
|
|
Davy
(Euronext Growth Adviser and Joint Broker)
|
+353 (0) 1
679 6363
|
Anthony Farrell, Niall
Gilchrist
|
|
|
|
Walbrook PR (Financial PR
& IR)
Stephanie
Cuthbert / Phillip Marriage /
Louis Ashe-Jepson
|
+44 (0) 20
7933 8780 or hvivo@walbrookpr.com
+44 (0)
7796 794 663 / +44 (0) 7867 984 082 /
+44 (0) 7747 515 393
|
|
|
|
| |
Notes to
Editors
About
hVIVO
hVIVO plc
(ticker: HVO) (formerly Open Orphan plc) is a fast growing
specialist contract research organisation (CRO) and the world
leader in testing infectious and respiratory disease vaccines and
therapeutics using human challenge clinical trials. The Group
provides end-to-end early clinical development services to its
large, established and growing repeat client base, which includes
four of the top 10 largest global biopharma companies.
The Group's fast-growing services business
includes a unique portfolio of 11 human challenge models, with a
number of new models under development, to test a broad range of
infectious and respiratory disease products. The Group has world
class challenge agent manufacturing capabilities, specialist drug
development and clinical consultancy services via its Venn Life
Sciences brand, and a lab offering via its hLAB brand, which
includes virology, immunology biomarker and molecular testing. The
Group offers additional clinical field trial services such as
patient recruitment and clinical trial site services.
hVIVO runs challenge trials in London - its
new state-of-the-art facilities in Canary Wharf opened in 2024 and
is the world's largest commercial human challenge trial unit, with
highly specialised on-site virology and immunology laboratories,
and an outpatient unit. To recruit volunteers / patients for its
studies, the Group leverages its unique clinical trial recruitment
capability via its FluCamp volunteer screening
facilities in London and Manchester.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
CROUPURGMUPCGQG
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024